Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Buy
Sell